Celtic Pharma Sees a Role for Private Equity in Biotech
This article was originally published in Start Up
Executive SummaryThe recently launched private equity firm Celtic Pharma aims to bridge the gap between biotech companies that have trouble financing R&D for mid- to late-stage projects and the Big Pharma firms desperate to rebuild their pipelines. The group's first fund, at around $1 billion, aims to bring together approximately 20 late-stage projects, take each through to regulatory approval, and license them out to the highest bidder.
You may also be interested in...
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.